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DNA-binding and functional assays examined the role played by NF-IL6 in regulation of HIV-1 transcription in human
monocyte/macrophages (U937 cells), stimulated with LPSPMA. When incubated with nuclear extracts from stimulated
cells, a region (189/147), containing the major NF-IL6-binding sequence and the USF site, interacted selectively with USF1
and USF2. Anti-C/EBP reacted poorly with the complexes produced with the wild-type probe. In contrast, complex formation
with NF-IL6 was clearly evident in experiments analyzing a probe containing an insertion in the USF site. In functional assays,
increasing concentrations of a decoy against NF-IL6 reduced gene expression from the LTR of the wild-type HIV-1 variant,
supporting a critical role for NF-IL6 in regulation of HIV-1 transcription in stimulated monocyte/macrophages. The decoy also
reduced gene expression from a deletion construct lacking NF-IL6-binding sequences. The results implied that in LPSPMA-
stimulated monocyte/macrophages, the endogenous NF-IL6 could act via a site-independent pathway in upregulation of
HIV-1 transcription. Analysis of a short DNA segment, containing the 189/147 region, suggested functional interactionsINTRODUCTION
Understanding the mechanisms that activate HIV-1 is
central to effective eradication of the HIV-1 disease (re-
viewed by Tang et al., 1999). Clinical studies have shown
that in infected individuals, the use of highly potent
antiviral agents can suppress HIV-1 replication and re-
duce the levels of HIV-1 RNA to below the limits of
detection in blood (see, for example, Chun et al., 1997a,b;
Perelson et al., 1997; Wong et al., 1997). However, evi-
dence suggests that the current combination of drug
regimens do not fully eradicate the disease. In studies of
the peripheral blood of patients with complete and sus-
tained plasma viremia, evidence supported the existence
of replication-competent and latent forms of the virus
(Chun et al., 1997a,b; Perelson et al., 1997; Wong et al.,
1997). Latent forms of the virus may include transcrip-
tionally dormant, integrated proviral DNA, and low levels
of persistent active virus (Chun et al., 1997a,b). In vitro
assays have shown that upon cellular stimulation, latent
HIV-1 is activated to produce elevated levels of infectious
particles (Wong et al., 1997; Chun et al., 1997a,b).
Depending on cell type, a variety of biological and
chemical agents can activate HIV-1 transcription leading
to virus production (reviewed by Tang et al., 1999). Acti-
vators of HIV-1 include cytokines, the tumor-promoting
agent PMA, and a group of bacterial lipopolysaccharides
collectively referred to as LPS (reviewed by Roebuck and© 2002 Elsevier Science (USA)
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256Saifuddin, 1999). Long-terminal repeat (LTR)-directed
transcription is regulated through several pathways in-
volving various cellular proteins including factors that
direct chromatin remodeling, factors that serve as com-
ponents of the basal transcriptional machinery, and tran-
scription factors that act through protein–DNA, protein–
protein, and protein–ligand interactions (reviewed by
Marzio and Giacca, 1999; Roebuck and Saifuddin, 1999).
The HIV-1 LTRs are selectively recognized by several
cellular transcription factors including Sp1, NF-B, USF,
and NF-IL6 (Jones et al., 1986; Nabel and Baltimore, 1987;
Lu et al., 1990; Tesmer et al., 1993). Two Sp1 sites are in
the immediate upstream of the TATA element, regulated
by the components of the basal transcriptional machin-
ery. Two NF-B sites act in cellular responses controlled
by stimulating agents including TNF, LPS, and PMA
(Nabel and Baltimore, 1987; Pomerantz et al., 1990). USF
binds an E-box upstream of the NF-B sites. USF has
been implicated in exerting either negative or positive
control on HIV-1 transcription (Lu et al., 1990; Giacca et
al., 1992; di Fagagna et al., 1995; Naghavi et al., 2001).
The LTR of HIV-1 variants may include one or several
sites for binding NF-IL6 (Tesmer et al., 1993). The major
NF-IL6-binding site (site I) overlaps the USF-binding se-
quence. This site has been found in the LTR of several
HIV-1 variants (Tesmer et al., 1993; Mondal et al., 1995;
Henderson et al., 1995; Ruocco et al., 1996) and appears
in all B subtype HIV-1 isolates from Southern Africa
(Zacharova et al., 1997). The LTR of HIV-1 variants mayof NF-IL6 and USF. In activated cells exogenous NF-IL6
segment containing the NF-B sites, supporting functional
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include a second NF-IL6-binding site (site II) in the im-
mediate upstream of the NF-B-binding sequences (Tes-enhan
interac
mer et al., 1993; Stein et al., 1993; Mondal et al., 1995;
Henderson et al., 1995; Ruocco et al., 1996). Another
NF-IL6-binding sequence (site III) appears further up-
stream. However, this sequence does not conform to the
NF-IL6 consensus-binding site and interacts poorly with
NF-IL6 (Tesmer et al., 1993).
Understanding of how NF-IL6 regulates HIV-1 tran-
scription is central to identifying the pathways through
which HIV-1 could be activated since studies have
shown that NF-IL6, also known as human C/EBP, plays
a key role in the control of gene expression in cellular
responses mediated by cytokines and LPS as a conse-
quence of bacterial infection (Akira et al., 1990; Akira and
Kishimoto, 1992). However, the mechanism of LTR regu-
lation by NF-IL6 is not fully understood. Specifically, the
results of several studies have shown that in transient
expression assays, activation of HIV-1 expression by
NF-IL6 can occur in the absence of the NF-IL6-binding
sequences, suggesting that NF-IL6 might exert control
through other regulators of HIV-1 transcription (see, for
example, Tesmer et al., 1993; Mondal et al., 1995; Ruocco
et al., 1996; Tesmer and Bina, 1996; Schwartz et al., 2000).
However, the results of studies from another laboratory
indicated that in human monocyte/macrophages (U937
cells) stimulated with LPSPMA, at least one NF-IL6-
binding sequence was required for the upregulation of
HIV-1 expression by NF-IL6 (Henderson et al., 1995, 1996;
Henderson and Calame, 1997).
Since more recent data indicated that in U937 cells
stimulated with LPSPMA, the endogenous NF-IL6
could act through functional interactions with other reg-
ulators of LTR-mediated transcription (Yang, 1999), we
examined the regulation of HIV-1 transcription in acti-
vated U937 cells by using a decoy against NF-IL6. DNA-
binding assays were done to closely evaluate interac-
tions of nuclear proteins with the LTR regions implicated
in binding NF-IL6. Transient expression experiments
were done to examine potential mechanism of NF-IL6-
directed regulation of HIV-1 transcription.
RESULTS
Interactions of nuclear proteins with the 189/147
region of HIV-1 LTR
For studies of HIV-1 regulation in activated monocyte/
macrophages, experiments were designed to closely ex-
amine protein interactions with DNA fragments contain-
ing the NF-IL6 and USF sites in the 189/147 region of
the HIV-1 LTR (Fig. 1). One set of assays analyzed the
wild-type DNA in electrophoretic mobility shift assays
(EMSAs). With nuclear extracts from unstimulated cells,
the probe produced a cluster of closely spaced bands
(Fig. 2). With extracts from cells stimulated with
LPSPMA, the probe produced a similar pattern of pro-
tein–DNA interactions (Fig. 2). In the assays, increasing
amounts of the cold probe competed effectively for for-
mation of the major bands (Fig. 2A, Lanes 2, 3, 9, 10).
Sequences with an insertion in the NF-IL6 site, but an
intact E-Box (providing the USF site), also competed
effectively for complex formation (Fig. 2A, Lanes 4, 5, 11,
12). In contrast, a fragment containing an insertion in the
E-box but an intact NF-IL6 site could not compete with
the probe for protein binding (Fig. 2A Lanes 6, 7, 13, 14).
Specific antibodies were added to the DNA-binding
reactions to identify the major components of the com-
plexes formed with the wild-type 189/147 region (Fig.
2B). In the assays, anti-USF reacted with nearly all of the
complexes formed with the wild-type sequence (Fig. 2B,
Lanes 5 and 12), indicating that USF was a major com-
ponent of the bands detected in EMSAs. A fraction of the
bands was supershifted with anti-USF-1 (Lanes 2 and 9);
the other fraction reacted with anti-USF-2 (Lanes 3 and
10). Inclusion of antibody to both USF-1 and USF-2
shifted nearly all of the complexes formed with the wild-
type probe (Lanes 5 and 12). With anti-C/EBP, we did
not detect supershifted bands in assays analyzing ex-
tracts from unstimulated cells (Lane 4). With extracts
from cells stimulated with LPSPMA, anti-C/EBP pro-
duced faint, barely detectable, supershifted bands (Fig.
2B, Lane 11). Overall, the results implied that the com-
plexes formed with the wild-type DNA contained primar-
ily USF1 and USF2.
To further evaluate this finding, for EMSAs we de-
signed a probe containing an insertion in the USF site
while maintaining the NF-IL6-binding sequence intact.
This probe was incubated with nuclear extracts prepared
from stimulated or unstimulated U937 cells. The bands
produced with extracts from unstimulated cells (0 h)
were diffused and relatively low in intensity (Fig. 3, Lane
1). Anti-C/EBP reacted with a fraction of the diffused
bands (Fig. 3, Lane 2), indicating that the extracts from
unstimulated cells contained low levels of NF-IL6. Sig-
nificantly higher amounts of NF-IL6-containing com-
plexes were obtained with extracts from cells stimulated
FIG. 1. Organization of protein-binding elements in the LTR of the
HIV-1 variant analyzed in functional and DNA-binding assays. The LTR
of the variant included the Sp1 sites (80/40), the NF-B sites
(108/78), and the region (189/147) containing the NF-IL6 site I
and the overlapping E-box defining the USF site. The variant did not
contain the consensus NF-IL6 site II flanking the NF-B-binding se-
quences. The wild-type construct (pC15XE), analyzed in functional
assays, included the 339 to 83 region of the variant LTR. The
deletion construct (pC15XP) lacked the region upstream position
163, including the NF-IL6 site I and the USF site.
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with both LPS and PMA (Fig. 3, Lanes 3 and 5). Generally,
the fraction of NF-IL6-containing complexes increased
as a function of cellular stimulation time; see, for exam-
ple, the level observed with extracts from cells stimu-
lated for 66 h with LPSPMA (Fig. 3, Lanes 5 and 6).
Additional assays evaluated protein interactions with a
probe containing an insertion in the NF-IL6 site while
maintaining the USF site intact. The protein-binding pat-
tern detected for this probe (data not shown) was similar
to the pattern observed for the wild-type sequence (Fig.
2). Overall the data indicated that in studies of extracts
from U937 cells stimulated with LPSPMA, USF1 and
USF2 dominated the complexes formed with the wild-
type sequence (Fig. 2) even though the sequence con-
tained an intact NF-IL6 site and even though the produc-
tion of NF-IL6 was clearly induced in the stimulated cells
(Fig. 3).
Regulation of HIV-1 transcription by NF-IL6 in
monocyte/macrophages stimulated with LPSPMA
To test the involvement of NF-IL6 in regulation of HIV-1
transcription, we designed an experiment using a decoy
to inhibit the activity of NF-IL6 in U937 cells stimulated
with LPSPMA. This experiment was designed since
supershift assays did not detect significant amounts of
NF-IL6 in complexes formed with the native 189/147
region of the LTR (Fig. 2). The LTR of the HIV-1 variant
examined in functional assays (Fig. 1) included a single
FIG. 3. Interactions of nuclear proteins with isolated NF-IL6 site. The
fragment (189/147mEbox) used as probe contained an intact NF-IL6
site but an insertion in the overlapping E-box defining the USF site. The
probe was incubated with nuclear extracts from unstimulated U937
cells (0 h), or nuclear extract from cells stimulated with LPSPMA for
48 or 66 h. Lanes 2, 4, and 6 included antibody (A) to C/EBP.
FIG. 2. Interactions of nuclear proteins with the region containing the NF-IL6 and USF sites. The wild-type sequence (189/147) was used as
probe to analyze nuclear extracts from U937 cells, mock stimulated (shown as ) or stimulated (shown as ) with LPS and PMA. (A) Competition
experiments included 200 or 400 of the following sequences: Specific competitor DNA (S.P.); a fragment containing an insertion in the NF-IL6 site
(189/147mNF-IL6); or a fragment containing an insertion in the Ebox (189/147mEbox), defining the USF site. (B) The reactions were
supplemented with antibodies (A) against USF-1, USF-2, C/EBP, or in combination, as indicated above each lane. The brace marks the position of
diffused supershifted bands produced with anti C/EBP.
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site for binding NF-IL6 (site I, 173 to 165), and con-
tained a naturally occurring mutation in the NF-IL6 site II,
flanking the NF-B-binding sequences (Tesmer et al.,
1993; Tesmer and Bina, 1996).
The design of functional assays relied on an expres-
sion construct (CMV500–4hep-CEBP) that produced in
cells a peptide inhibiting the activity of C/EBPs. The
inhibitor included acidic residues in the N-terminal re-
gion of the Leucine Zipper (Krylov et al., 1995). We
expected that the inhibitor would act as a dominant
negative regulator of NF-IL6 by forming a coiled-coiled
structure with the bZIP region to interfere with the DNA-
binding and transactivation properties of NF-IL6 (Krylov
et al., 1995). In designing the experiment, we reasoned
that if NF-IL6 functioned in the activation of HIV-1 gene
expression in stimulated cells, then production of the
4hep-CEBP peptide should downregulate LTR-mediated
transcription in stimulated cells through dimerization
with the induced NF-IL6. To test this hypothesis, in func-
tional assays increasing amounts of CMV500–4hep-
CEBP were cotransfected with a selected reporter con-
struct. The assays were supplemented with the empty
CMV vector to maintain a constant amount of DNA.
Subsequently the transfected cells were mock stimu-
lated or stimulated with LPSPMA, to induce the pro-
duction of endogenous NF-IL6 (Fig. 4).
The effect of the decoy was tested on the activity of
two reporter constructs: a wild-type construct (pC15XE)
and a deletion mutant (pC15XP). The wild-type con-
struct contained the LTR segment between nucleotides
339 and 83. The deletion mutant lacked the USF site,
the NF-IL6 site, and sequences further upstream (Fig. 1).
In transient expression assays, in the absence of the
decoy, both constructs responded positively to LPS and
PMA stimulation, as expected (Fig. 4). Increasing
amounts of the decoy reduced significantly the activity of
the wild-type construct, supporting a central role for
NF-IL6 in activation of HIV-1 transcription in monocyte/
macrophages stimulated with LPSPMA (Fig. 4). In-
creasing amounts of the decoy also reduced gene ex-
pression from the wild-type construct in mock-stimulated
cells, indicating that the low levels of NF-IL6 in unstimu-
lated cells (Fig. 3) contributed to the background level of
HIV-1 transcription in unstimulated monocyte/macro-
phages (Fig. 4). We noted that in the assays, increasing
amount of the decoy also reduced the activity of the
deletion construct (pC15XP) that lacked sequences up-
stream position 163: including the NF-IL6 and USF site
(Figs. 1 and 4). Krylov et al. (1995) have shown that in
functional assays the decoy acted selectively against
transactivators containing C/EBP zipper but not those
containing GCN4 zipper.
The results of the experiments described for the de-
letion mutant implied that the endogenous NF-IL6 was
acting in the absence of a specific site for binding NF-
IL6, since the LTR variant analyzed in the assays in-
cluded a point mutation in the NF-IL6-binding sequence
(site II) flanking the NF-B sites (Fig. 1). This sequence
was expected not to bind NF-IL6. Nonetheless, we de-
signed experiments to evaluate directly the interactions
of nuclear extracts with the segment (114/106) that
flanks the NF-B site (Fig. 5), to test whether the naturally
mutated segment interacted with NF-IL6. For compara-
tive analysis, we also synthesized a pair of oligos
(mC3LTR) containing a five-base substitution in the
NF-B flanking sequences since previous studies found
that this substitution significantly altered the functional
activity of the LTR in responses mediated by NF-IL6
(Henderson et al., 1995, 1996; Henderson and Calame,
1997).
In EMSAs, with nuclear extracts from unstimulated or
stimulated cells, the probe consisting of the 114/106
region of the variant LTR produced a nonspecific band
but not any specific complex (Fig. 5B, Lanes 7 to 12).
Therefore, as predicted, the natural LTR variant analyzed
in our functional assays did not contain the NF-IL6-
binding sequence adjacent to the NF-B sites. However,
in the assays, the mC3LTR oligos interacted with pro-
teins in nuclear extracts from unstimulated cells to pro-
duce a specific band and a nonspecific band (Fig. 5A,
Lanes 1 to 6). Formation of the specific complex could be
competed with the cold probe defining the m3LTR muta-
FIG. 4. Effect of a decoy (CMV500–4hep-CEBP) against NF-IL6 on the
wild-type LTR and a deletion mutant. The assays analyzed the func-
tional activity of two constructs (pC15XP and pC15XE) in unstimu-
lated U937 cells (dash line) and in cells stimulated with LPSPMA
(solid line). The assays were done as a function of increasing amounts
of CMV500–4hep-CEBP, an inhibitor of C/EBPs (Krylov et al., 1995). The
construct pC15XE represents the wild-type DNA; pC15XP has a
deletion extending to position 163 (Fig. 1).
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tion (Fig. 5A, Lane 2) but not with the naturally occurring
sequence (114/106(XE)) containing a mismatch with
the consensus NF-IL6-binding site (Fig. 5A, Lane 3). The
results suggest that the engineered mutation in m3LTR
created a binding site for another nuclear protein. Fur-
thermore, we observed a different DNA-binding pattern
when the mC3LTR oligos were incubated with nuclear
extracts from stimulated cells (Fig. 5C). With nuclear
proteins from stimulated cells, the probe produced low-
intensity diffused bands, migrating above the nonspecific
band (Fig. 5C, Lane 5). The cold probe eliminated the
specific complexes formed with mC3LTR while the114/
106(XE) oligos did not (Fig. 5). Anti-C/EBP super-
shifted the diffused bands produced with extracts from
stimulated cells. The results implied that the complex
formed with the mC3LTR and nuclear proteins from stim-
ulated cells included low levels of NF-IL6.
Functional interactions involving NF-IL6
The experiments in the previous section showed that
in cells stimulated with LPSPMA, a decoy against NF-
IL6 reduced the activity of a construct that did not contain
consensus sites for binding NF-IL6 (Fig. 4). The results
implied that when examined in the context of a wild-type
LTR, in stimulated cells NF-IL6 could act in the absence
of consensus NF-IL6-binding elements. In another set of
assays we tested the activity of a construct containing
the wild-type and mutated 189/147 segment, cloned
in the immediate upstream of the basal LTR sequences
(40 to 83, Fig. 6). Under our standard transfection
assays, using 5 g of reporter DNA, the native 189/
147 region was active, but the assays did not detect a
response to cellular stimulation with LPSPMA (Fig. 7).
A very small response was observed when 10 g of the
construct was analyzed in the assays (Fig. 7).
In studies of mutated constructs (Fig. 6), CAT activity
was nearly abolished when an insertion was made in
either the USF site or the NF-IL6 site (Fig. 7). This finding
may imply that the NF-IL6 site was responsible for the
activity obtained for the isolated 189/147 region.
However we noted that gene activity and response to
cellular stimulation was not obtained for the construct
FIG. 5. Interactions of nuclear proteins with the segment flanking the NF-B sites. Two probes were analyzed in EMSAs: mC3LTR and
114/106(XE). (A) The probe mC3LTR contained a 5-bp substitution in the NF-IL6 consensus site in the 114 to 106 region (Henderson et al.,
1995, 1996; Henderson and Calame, 1997). (B) The probe 114/106(XE) is from the 114 to 106 region of the variant analyzed in our functional
assays. Each probe was incubated with nuclear extracts from unstimulated U937 cells () or from cells stimulated () for 20 h with LPSPMA. Some
reactions contained a competitor DNA (114 to 106 oligos, or mC3LTR oligos), as indicated above the corresponding lanes. The arrow points to
the specific complex generated from interactions of the mC3LTR oligos with proteins in extracts from unstimulated cells; brace marks the position
of diffusely migrating specific bands; N.S. points to a nonspecific band. (C) The mC3LTR oligos were analyzed using nuclear extracts from U937 cells
stimulated, for 48 h, with LPSPMA. The reactions in Lanes 2–8 contained a competitor DNA (S.P.), 114/106 oligos, or the NF-B-binding
sequences, as indicated above the corresponding lanes. Lane 9 contained antibody (A) to C/EBP. The brace marks the position of diffusely
migrating specific bands produced with nuclear extracts from U937 cells stimulated with LPSPMA. The arrow on the left points to the specific
complex generated from interactions of the mC3LTR oligos with proteins in extracts from unstimulated cells; N.S. points to a nonspecific band.
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containing an intact NF-IL6 site but an insertion in the
USF site (Fig. 7). In DNA-binding assays, mutations in the
USF site caused high levels of NF-IL6-containing com-
plexes in studies of extracts from stimulated cells (Fig. 3).
The results indicated that in the context of isolated189/
147 region, USF did not act in the absence of NF-IL6
and NF-IL6 did not act in the absence of USF. This result
suggests functional interactions of NF-IL6 and USF.
The data prompted assays to evaluate functional in-
teractions of NF-IL6 and NF-B in stimulated monocyte/
macrophages (Fig. 8). Previously several studies exam-
ined physical and functional interactions of NF-IL6 with
subunits of NF-B (LeClair et al., 1992; Stein and Bald-
win, 1993; Stein et al., 1993; Ruocco et al., 1996). We
wished to test the effect of exogenous NF-IL6 on the
activity of HIV-1 B sites in monocyte/macrophages stim-
ulated with LPSPMA. For this analysis, native and mu-
tated NF-B sites (Nabel and Baltimore, 1987) were
cloned in the immediate upstream of the basal region of
the LTR (Fig. 6) to evaluate their relative activities in
cotransient expression assays.
In the assays, as expected, the isolated NF-B sites
responded to cellular stimulation with LPSPMA, while
mutated NF-B sites did not (Fig. 8). In unstimulated and
stimulated cells, exogenous NF-IL6 increased the activity
of the CAT gene driven by native NF-B sites (Fig. 8). In
cells stimulated with LPSPMA, the response to NF-IL6
was relatively high. In stimulated cells, the construct
containing mutated B sites also responded to NF-IL6
(Fig. 8). A small response also was detected for the basal
region, as previously observed (Tesmer and Bina, 1996).
FIG. 6. Organization of constructs containing isolated segments from
the LTR. For functional studies, several segments were cloned up-
stream the basal sequences (40 to83). One segment (108 to78)
included the NF-B sites. Another segment (189 to 147) included the
overlapping NF-IL6 and USF sites (Fig. 1). Mutated segments contained
replacements in the NF-B sites, an insertion in the NF-IL6 site, or an
insertion in the USF site. In the diagram, the modified sequences are
marked by an X. The basal sequences are designated as LTRb.
FIG. 7. Functional activity of isolated NF-IL6 and USF sites. Functional assays evaluated the following constructs: 189/147wtLTRb, the native
sequence; 189/147mNF-IL6LTRb, containing an insertion in the NF-IL6 site; 189/147mEboxLTRb, containing an insertion in the E box defining
the USF site. LTRb corresponds to the basal segment (Fig. 6). The experiments examined two different concentrations (5 and 10 g) of each construct
in stimulated cells () and in unstimulated cells ().
FIG. 8. The effect of exogenous NF-IL6 on gene expression driven by
the NF-B sites. The constructs included intact or mutated NF-B sites
cloned upstream the basal region (Fig. 6). The assays were done in
unstimulated U937 cells (shown as ) or in LPS and PMA stimulated
cells (shown as ), in the presence () or absence of an NF-IL6
producing construct (CMV NF-IL6).
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DISCUSSION
The results of the studies shown in this article agree
with several lines of evidence, indicating that the mech-
anism of regulation of HIV-1 transcription by NF-IL6 is
complex. To regulate LTR-mediated transcription, NF-IL6
can functionally interact with Sp1 (Tesmer and Bina,
1996; Schwartz et al., 2000), with USF (Fig. 7), with NF-B
(Fig. 8; also see Mondal et al., 1995; Ruocco et al., 1996),
with COUP-TF (Schwartz et al., 2000), and with ATF/CREB
family members (Ross et al., 2001). Thus, while in micro-
glial and oligodendroglioma cells, NF-IL6 functioned as a
potent activator of LTR-driven transcription and NF-IL6
could act via the minimal 40/80 region of the LTR,
implying that the NF-IL6-binding elements were not es-
sential for LTR activation by NF-IL6 (Schwartz et al.,
2000). Furthermore, functional interactions of NF-IL6 and
Sp1 led to synergistic transcriptional activation of the
LTR in oligodendroglioma cells (Schwartz et al., 2000).
Similarly, in human hepatoma HepG2 cells, NF-IL6 func-
tionally interacted with Sp1 to upregulate transcription
through the minimal 40/83 region of the LTR (Tesmer
and Bina, 1996). In activated Jurkat cells, exogenous
NF-IL6 significantly increased the level of the LTR re-
sponse to cellular stimulation through a mechanism that
did not require the NF-IL6-binding elements (Buckner et
al., 2002). In NTera-2 cells (Ruocco et al., 1996) and in
activated monocyte/macrophages (Fig. 8), NF-IL6 could
upregulate LTR-mediated transcription through func-
tional interactions with NF-B.
Evidence has further shown that in some cases NF-IL6
can act indirectly to regulate the expression of cellular
genes. For example, in beta pancreatic cells, NF-IL6
inhibited transcription of the rat insulin I gene not
through binding DNA but through interaction with a hep-
tad leucine repeat sequence within the activation do-
main 2 of the bHLH transcription factor E47 (Lu et al.,
1997). Studies of the rat insulin gene indicate that the
leucine zipper in NF-IL6 and its family members (C/EBPs)
could play multiple roles in regulation of gene expres-
sion.
In addition to functional or physical interactions with
several transcription factors, including E47 (Lu et al.,
1997), the p50 subunit of NF-B (LeClair et al., 1992;
Ruocco et al., 1996), COUP-TF (Schwartz et al., 2000), and
ATF/CREB family members (Ross et al., 2001), NF-IL6
interacts with mediators of transcription. For example,
the chicken homolog of NF-IL6 interacts with p300/
CREB-binding protein CBP (Mink et al., 1997). Two-hy-
brid-type experiments supported a critical role of the
amino terminal sequences of the chicken bZIP protein in
interactions with CBP (Mink et al., 1997) and implied that
transcriptional transactivation by CBP might require in-
tact homodimers of the bZIP protein. Extending these
results to studies of HIV-1 regulation would suggest that
heterodimers of NF-IL6 that lack the amino-terminus of
the protein should be inactive in LTR-mediated transcrip-
tion. Consistent with this interpretation is repression of
LTR-mediated transcription by heterodimers consisting
of NF-IL6 and a decoy against NF-IL6 (Fig. 4).
For studies of regulation of HIV-1 transcription by NF-
IL6, a study made two-site-directed nucleotide replace-
ments to derive constructs that lacked NF-IL6 site I or
site II (Henderson et al., 1995). One replacement (mc2)
was made to destroy the NF-IL6-binding sequence that
overlaps the USF site. The other (mc3) was made to
destroy the NF-IL6-binding sequence that flanks the
NF-B sites. The constructs and their derivatives have
been used in several studies (see, for example, Hender-
son et al., 1995, 1996; Henderson and Calame, 1997). The
results of these studies indicated that one NF-IL6-bind-
ing sequence was required for the regulation of HIV-1
transcription by NF-IL6. In contrast, our data revealed
that a decoy against the endogenous NF-IL6 reduces
gene activation by a wild-type LTR and reduced the
activity of a deletion construct lacking binding sites for
NF-IL6. The results indicate that in activated monocyte/
macrophages, NF-IL6 may act in a site-independent
fashion (Fig. 4).
To understand the reason for the disagreements in the
literature, we have inspected and closely examined the
sequence of mc2 and mc3 analyzed in previous reports
(Henderson et al., 1995, 1996; Henderson and Calame,
1997). Our studies indicate that creation of mc3 resulted
in a binding site for a cellular protein (Fig. 5). It seems
possible that interactions of this protein with mc3 may
affect the results of assays using mc3 and its derivatives.
Inspection of the sequence of mc2 indicates that in
addition to destroying the NF-IL6-binding sequence that
overlaps the USF site, mc2 destroys a sequence that can
potentially interact with TCF20. A binding site for this
novel transcription factor exists in the LTR of some HIV-1
variants. In fact, a partial cDNA for TCF20 was isolated
using a DNA segment that included the NF-IL6 and USF
site, from the LTR of an HIV-1 variant (Rajadhyaksha et
al., 1998). TCF20, also known as SPBP (Sanz et al., 1995),
is relatively large. This novel transcription factor includes
several domains that stimulate the activity of various
transcription factors including c-Jun, Ets1, Sp1, and Pax6
(Rekdal et al., 2000). TCF20/SPBP also interacts with
RNF4 (SNURF), which has been shown to interact with
steroid hormone receptors and Sp1 (Lyngso et al., 2000).
Evidence suggests that NF-IL6 can tether to TCF20 and
thus may act indirectly to exert control on LTR-mediated
transcription (J. Gu and M. Bina, unpublished observa-
tions).
As observed for NF-IL6, USF also has been shown to
affect LTR-directed transcription independent of se-
quence variations that would reduce interactions of USF
with HIV-1 DNA (Naghavi et al., 2001). In T cells, USF
functionally interacted with Ets-1 to upregulate LTR-di-
rected transcription (Sieweke et al., 1998). Evidence in-
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dicated that in the absence of USF site, USF upregulated
LTR-mediated transcription through functional interac-
tions with factors that bind the initiator element in the
basal region of the HIV-1 LTR (Du et al., 1993).
In fact, several studies support a central role for the
basal segment in the control of HIV-1 transcription
(Kashachi et al., 1994; Estable et al., 1996; Tesmer and
Bina, 1996; Schwartz et al., 2000). The basal segment
may play a crucial role in the activation of HIV-1 tran-
scription since the rapidly evolving HIV-1 variants often
can tolerate large deletions and mutations in the LTR and
remain responsive to cellular stimulation (Kashachi et al.,
1994; Estable et al., 1996). In this context, the site-inde-
pendent pathway of HIV-1 regulation by NF-IL6 might be
significant. Specifically, in the LTR of rapidly evolving
HIV-1 variants, the sequence elements that bind NF-IL6
can change (Estable et al., 1996; Ross et al., 2001), but in
activated cells, NF-IL6 would act to upregulate the pro-
duction of variants that contain a native basal region and
one or more intact sites for other transcription factors
that bind specific sequence elements in the LTR. This
mechanism predicts a central role for NF-IL6 in support-
ing the production and propagation of rapidly evolving
HIV-1 variants in HIV-1-infected individuals, particularly
when they suffer from episodes of infection with gram-
negative bacteria (Pomerantz et al., 1990) and when the




Human promonocytic cell line U937 (American Type
Culture Collection) was grown in RPMI 1640 media (Ir-
vine Scientific) supplemented with 10% heat-inactivated
fetal bovine serum (Gibco), 100 U/mL penicillin, 100
g/mL streptomycin, 5.5 mM -mercaptoethanol, and 1
mM sodium pyruvate (Gibco). For cellular stimulation,
LPS stock was prepared by dissolving lyophilized LPS
(Escherichia coli strain 055:B5, Sigma) in sterile ddH2O.
A solution (10 g/mL) of stock PMA (99%-TLC purified,
Sigma) was prepared in DMSO. U937 cells were stimu-
lated by adding aliquots of stock solution of LPS (2
g/mL final concentration) and PMA (10 ng/mL final
concentration) to the culture media. Mock stimulation
was performed with the solvents used for preparing LPS
and PMAs.
Electrophoretic mobility shift assays
Nuclear extracts were prepared from unstimulated and
LPSPMA-stimulated cells as previously described (Doyle
et al., 1994). For studies of NF-IL6 site I, chemical synthesis
was done to produce double-stranded oligonucleotides
corresponding to the189 to147 region of the HIV-1 long
terminal repeat. The oligos were annealed and cloned.
Recombinant plasmids were sequenced to ensure accu-
racy (Tesmer et al., 1993). We followed a similar strategy for
obtaining a plasmid (187/147mNF-IL6) containing an
insertion, three nucleotides (ATTTCTAGATCA), in the 189
to 147 region of the HIV-1 LTR (Tesmer and Bina, 1996).
Mutated USF site (189/147mEbox) was obtained from
cloning synthetic DNA containing an insertion, two nucle-
otides (CACTAGTG), in the USF site in the 189 to 147
region of the HIV-1 LTR (Tesmer and Bina, 1996).
For studies of NF-IL6 site II, double-stranded oligonu-
cleotides (agcttTCGAGCTTGTTACAAGGctgca top strand)
were synthetically produced and cloned. The sequence,
named 114/103(XE), defines the 114 to 103 re-
gion of the LTR of an HIV-1 variant containing a point
mutation in the NF-IL6 site. Another sequence (agcttTC-
GACAGCTGTACAAGGctgca top strand) selected for
analysis corresponded to mC3LTR-containing substitu-
tions in the NF-IL6 site in 114/103 region of the HIV-1
LTR (Henderson et al., 1995).
The probe analyzed in EMSAs was labeled with 32P
and subsequently incubated with 4 g nuclear extracts
in reactions that included 1 g poly(dI-dC) in 15 mM
HEPES (pH 7.9), 80 mM NaCl, 1 mM EDTA, 1 mM DTT,
10% glycerol, and 300 g/ml BSA. The reactions were
incubated on ice for 15 to 30 min. The products were
separated by electrophoresis at 4°C, at 300–250 V, in
3.5% polyacrylamide gels containing 2.5% glycerol and
TGE [25 mM Tris (pH 8.3), 190 mM glycine, 1 mM EDTA].
Competition experiments included unlabeled DNA frag-
ments (either derived from a construct or chemically
synthesized).
In supershift assays, the reactions were supple-
mented with 1 g of antibody obtained from Santa Cruz
Biotechnology: anti-C/EBP (catalog no. sc-150x, epitope
corresponding to an amino acid sequence mapping to
the carboxyl-terminus of C/EBP of rat origin, differs from
the corresponding human sequence by a single amino
acid); anti-USF-1 (catalog no. sc-229x, epitope corre-
sponding to an amino acid sequence mapping to the
carboxyl-terminus of USF-1 of human origin); USF-2 (cat-
alog no. sc-861x, epitope corresponding to an amino acid
sequence mapping to the amino-terminus of USF-2 of
mouse origin).
DNA constructs for transient expression assays
Previous reports described constructs pC15XE and
pC15XP (Tesmer et al., 1993; Tesmer and Bina, 1996).
Briefly, the wild-type construct (pC15XE) contains the
LTR segment from 339 to 83, cloned upstream the CAT
reporter gene. The construct was made by excising the
XhoI and PmlI fragment from pC15CATb (Tesmer et al.,
1993). The deletion mutant (pC15XP) was made by
excising the XhoI/EcoRV fragments from pC15CATb.
Several constructs were created by cloning specific
LTR-derived sequences upstream the basal region: 40
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to 83, designated as LTRb (Fig. 6). The constructs
included the following: 189/147wtLTRb (containing
the NF-IL6 site and the USF site); 189/147mNF-
IL6LTRb (containing three nucleotide insertion in the
NF-IL6 site but an intact USF site); and 189/147mE-
boxLTRb (containing an intact NF-IL6 site but two nucle-
otide insertion in the USF site) described above. Two
other constructs contained intact and mutated NF-B
sites cloned upstream basal region. Mutated NF-B sites
were made as previously described (Nabel and Balti-
more, 1987).
The expression construct for producing NF-IL6 has
been described (Tesmer et al., 1993). The expression
construct CMV500–4 hep-CEBP was generously pro-
vided by Dr. C. Vinson (NCI/NIH).
Transient expression assays
For functional assays, the constructs were isolated by
the alkaline lysis procedure (Sambrook et al., 1989) and
further purified on Qiagen DEAE columns. The constructs
were further sequenced to establish accuracy. The assays
were done in U937 cells. The cells were transfected by
electroporation (IBI GeneZapper 450/2500). The amount of
DNA used in transient expression assays was optimized in
titration experiments along with appropriate controls (Tes-
mer and Bina, 1996; Yang, 1999). Electroporation was done
at high cell density (at or above 2  107 cells/ml), at 300 V
and capacitance of 700 F.
After electroporation, the cells were incubated on ice
for 10 min and subsequently transferred to 10 ml of
culturing RPMI 1640 media including serum. For cellular
stimulation, LPS was dissolved in water (1 mg/ml) and
PMA in dimethyl sulfoxide (10 g/ml). The LPS or PMA
solutions were added to transfected cells to reach a final
concentration of 2 g/ml for LPS and 10 ng/ml for PMA
stimulation. Control mock inductions included an aliquot
of the solvents used for preparing the stock solutions of
the stimulating agents.
At 46–48 h after transfection, the cells were harvested
and the activity of chloramphenicol acetyltransferase in
cellular extracts was determined (Gorman et al., 1982;
Sambrook et al., 1989; Tesmer et al., 1993). The TLC
plates of CAT assays were initially analyzed by autora-
diography. Quantitative analysis was done using a Phos-
phoimager. Several low exposures of the plates were
analyzed to ensure linearity and reproducibility. The %
CAT conversion was then determined from the number of
pixels corresponding to the acetylated form of chloram-
phenicol, and the number of pixels corresponding to the
sum of acetylated and unacetylated chloramphenicol
(Yang, 1999). The data shown under Results provide the
average of several independent transfection assays.
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